Skip to main content
Article thumbnail
Location of Repository

Bloodborne Viral Hepatitis Infections among Drug Users: The Role of Vaccination

By Fabio Lugoboni, Gianluca Quaglio, Paolo Civitelli and Paolo Mezzelani


Drug use is a prevalent world-wide phenomenon and hepatitis virus infections are traditionally a major health problem among drug users (DUs). HBV and HCV, and to a lesser extent HAV, are easily transmitted through exposure to infected blood and body fluids. Viral hepatitis is not inevitable for DUs. Licensed vaccines are available for hepatitis A and hepatitis B. The purpose of this overview is to show some epidemiological data about HBV and the other blood-borne viral hepatitis among DUs and to summarize and discuss use of hepatitis vaccinations in this population. Successful vaccination campaigns among DUs are feasible and well described. We try to focus on the most significant results achieved in successful vaccination programs as reported in scientific literature. Vaccination campaigns among DUs represent a highly effective form of health education and they are cost-saving

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2001). A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine
  2. (2004). A syringe prescription program to prevent infectious disease and improve health of injection drug users.
  3. A vaccines WHO. position paper.
  4. (2007). A.; Nocchiero Study Group. Effectivenes of a multidisciplinary standarized management model in the treatment of chronic epatiti C in drug addicts engaged in detoxification programmes.
  5. (2005). Adherence to hepatitis B virus vaccination at syringe exchange sites.
  6. (2005). Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunization uptake.
  7. (2003). Changing epidemiology of hepatitis A: should we be doing more to vaccinate injecting drug users?
  8. (2000). Chronic hepatitis D: a vanishing disease? An italian multicenter study. Hepatology
  9. (2005). Co-infection by human immunodeficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
  10. (2002). Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction
  11. (2000). Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users partecipating in a syringe/needle exchange program.
  12. (2003). Delta hepatitis: an update.
  13. (1982). Disease Control and Prevention. Achievements in public health: hepatitis B vaccination—United States,
  14. (1990). Disease Control and Prevention. Incidence of acute hepatitis B-United States,
  15. (1999). Disease Control. Prevention of hepatitis A through active or passive immunization: recommendations of the
  16. (2002). Diseases Control and Prevention. Viral hepatitis and injecting drug users.
  17. (2000). Duration of viremia in hepatitis A virus infection.
  18. (2008). Economic evaluation of delivering hepatitis B vaccine to injection drug users.
  19. (2002). Epidemiology and prophylaxis of viral hepatitis: a global prospective.
  20. (2003). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report 2003: the state of the drugs problem in the European Union and Norway.
  21. (2006). Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend
  22. (2004). Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis
  23. (2003). Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.
  24. (2001). Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan,
  25. (1998). Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis
  26. (2004). Global overview of injecting drug use and HIV infection among drug users. AIDS
  27. (2006). HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors.
  28. (2004). HBV vaccination should be performed in service centres for drug users: an Italian experience.
  29. (2002). Hepatitis A epidemiology in England and Wales. Eurosurveillance Weekly
  30. (2003). Hepatitis A virus infections in injecting drug users.
  31. (2000). Hepatitis A virus vaccination among injecting drug users: do we have to change the vaccination schedule?
  32. (2001). Hepatitis A: old and new.
  33. (2008). Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs.
  34. (2002). Hepatitis B vaccination: how to reach risk groups. Vaccine
  35. (1998). Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine.
  36. (2008). Hepatitis B virus infection and immunization status in a new generation of injection drug users in
  37. (2004). Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend
  38. (2003). Hepatitis B virus. Immunization among young injection drug users in San Francisco, Calif: The UFO Study.
  39. (2003). Hepatitis C virus infection: prevalence, predictor variables and preventive opportunities among drug users in
  40. (2006). Hepatitis vaccination among drug users. Vaccine
  41. (1991). High compliance with a hepatitis B virus vaccination program among intravenous drug users.
  42. (2004). High Prevalence of Occult Hepatitis B in Baltimore injection drug users. Hepathol
  43. (2003). High seroprevalence of bloodborne viruses among streetrecruited injection drug users from Buenos Aires,
  44. (2006). Immunogenicity of recombinant hepatitis B vaccine in treatmentnaïve and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.
  45. (2007). Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case control study.
  46. (2008). Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy.
  47. (1997). Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine
  48. (2007). Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlandas. Vaccine
  49. (2007). Impact of hepatitis B vaccination in highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine
  50. (2002). Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev. Vaccines
  51. (2003). Isolated Antibody to Hepatitis B Core Antigen
  52. (2001). Isolated presence of antibody to hepatitis b core antigen in injection drug users: do they need to be vaccinated?
  53. (2007). Long-term immunogenicity of hepatitis B vaccination in a cohort of italian healty adolescents. Vaccine
  54. (2002). Managerial considerations in implementing hepatitis B vaccination programs among drug-using cohorts. Addiction
  55. (2000). Multiple modes of hepatitis A virus transmission among methamphetamine users.
  56. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia.
  57. (2002). No positive tests for syphilis in 6 years of observation among heroin users in north-eastern Italy.
  58. (2006). Office on Drug and Crime. World drug report. United Nations Publication:
  59. (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
  60. (2006). Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients.
  61. (2004). Poor validity of selfreported hepatitis B virus infection and vaccination status among young drug users.
  62. (1998). Prevalence and incidence rate of HIV,
  63. (1999). Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio
  64. (2005). Prevalence of hepatitis A among drug users in north-eastern Italy.
  65. (2001). Prevalence of hepatitis B and hepatitis C in a methadone clinic population : implication for hepatitis B vaccination.
  66. (2006). Prevalence of hepatitis B and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994-2002.
  67. (2003). Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention.
  68. (2004). Prevention of hepatitis A with the hepatitis A vaccine.
  69. (2003). Preventive care in the emergency department: should emergency departments conduct routine HIV screening? A systematic review.
  70. (2004). Progress on new vaccine strategies against chronic viral infections.
  71. (2004). Progressive decrease of Hepatitis B in a cohort of drug users followed over a period of 15 years: the impact of anti-HBV vaccination.
  72. (2001). Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program.
  73. (2004). reactogenicity and adherence of a combined hepatitis A and B vaccine in illicit drug users. Addiction
  74. (2004). reactogenicity and adherence with hepatitis A vaccination among drug users. Drug Alcohol Depend
  75. (1999). Response to HBV vaccine in relation to anti-HCV and antiHBc positivity: a study in intravenous drug addicts. Vaccine
  76. (2006). Risk behaviour and HIV, hepatitis B and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend
  77. (2004). Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in south-western
  78. (2002). Risk correlates of prevalent HIV, hepatitis B virus and hepatitis C virus infections among noninjecting heroin users.
  79. (2002). Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users.
  80. (1998). Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatol.
  81. (2006). Sexual risk for hepatitis B virus among hepatitis C virus-negative heroin and cocaine users. Epidemiol. Infect
  82. (2008). Smoking cassation during substance abuse treatment: what you need to know.
  83. (2002). The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study.
  84. (2002). The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis
  85. (2008). The global impact of vaccination against hepatitis B: a historical overview. Vaccine
  86. (1985). to establish the main causes of death. Addiction
  87. (2009). Two years' prospective collection of molecular and epidemiological data shows limited spread of
  88. (2008). Vaccination induced immunity to the hepatitis B virus among high-risk groups in Glasgow 1993-2001: evaluating the effectiveness of the UK’s selective immunization policy.
  89. (2007). Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect. Dis.
  90. (1997). Vaccines to prevent viral hepatitis.
  91. (2004). Wkly Rep.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.